TAKE Limited Stock Price Today (NSE: TAKE)
Fundamental Score
TAKE Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
TAKE Limited share price today is ₹17.67, down 4.43% on NSE/BSE as of 16 September 2026. TAKE Limited (TAKE) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹261.40 (Cr). The 52-week high for TAKE share price is ₹50.14 and the 52-week low is ₹10.09. At a P/E ratio of 20.55x, TAKE is currently trading below its industry average P/E of 39.78x. The company has a Return on Equity (ROE) of 42.11% and a debt-to-equity ratio of 0.00.
TAKE Limited Share Price Chart — NSE/BSE Historical Performance
TAKE Limited share price chart: -33.75% return over the past month. 52-week high ₹50.14, 52-week low ₹10.09.
TAKE Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹19.41 | ₹19.41 | ₹17.57 | ₹17.67 | 11.00L (Cr) | |
| ₹18.49 | ₹18.49 | ₹18.49 | ₹18.49 | 44.03K (Cr) | |
| ₹17.61 | ₹17.61 | ₹16.78 | ₹17.61 | 3.17L (Cr) | |
| ₹16.78 | ₹16.78 | ₹16.78 | ₹16.78 | 44.09K (Cr) | |
| ₹15.84 | ₹15.99 | ₹15.50 | ₹15.99 | 7.97L (Cr) | |
| ₹15.23 | ₹15.23 | ₹14.79 | ₹15.23 | 8.82L (Cr) | |
| ₹14.51 | ₹14.51 | ₹14.51 | ₹14.51 | 2.26L (Cr) | |
| ₹12.52 | ₹13.82 | ₹12.52 | ₹13.82 | 9.18L (Cr) | |
| ₹13.17 | ₹13.17 | ₹13.17 | ₹13.17 | 1.83L (Cr) | |
| ₹13.86 | ₹13.86 | ₹13.86 | ₹13.86 | 1.29L (Cr) |
TAKE Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹14.58 | ₹19.41 | ₹12.52 | ₹17.67 | +21.19% | |
| ₹21.99 | ₹24.39 | ₹15.34 | ₹15.34 | -30.24% | |
| ₹24.03 | ₹25.85 | ₹18.57 | ₹21.42 | -10.86% | |
| ₹30.80 | ₹31.85 | ₹25.29 | ₹25.29 | -17.89% | |
| ₹40.56 | ₹42.69 | ₹23.15 | ₹30.80 | -24.06% | |
| ₹40.41 | ₹50.14 | ₹40.41 | ₹42.69 | +5.64% | |
| ₹40.11 | ₹43.00 | ₹32.68 | ₹39.62 | -1.22% | |
| ₹42.75 | ₹49.94 | ₹40.65 | ₹42.22 | -1.24% | |
| ₹40.48 | ₹45.00 | ₹34.80 | ₹41.54 | +2.62% | |
| ₹31.49 | ₹41.20 | ₹30.99 | ₹39.94 | +26.83% | |
| ₹21.40 | ₹32.10 | ₹21.10 | ₹30.99 | +44.81% | |
| ₹12.06 | ₹24.95 | ₹12.06 | ₹21.66 | +79.60% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
TAKE Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
TAKE Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TAKE across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (42.11%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.49%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 20.55 vs Industry: 39.78)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (15.08% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.08% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (13.66x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹57.63 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Margin Pressure Concerns (-291.55%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
High Price-to-Book Ratio (12.59x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-216.76%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-41.25% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Low Promoter Commitment (5.19%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.28%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
TAKE Limited vs Healthcare Research, Analytics & Technology Peers
Peer Comparison - Healthcare Research, Analytics & Technology
Compare TAKE Limited with 8 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
TAKE LimitedTAKE Limited...Selected✓ TAKE • 532890 | 31.2/100 | ₹17.67₹18 | ₹261.40₹261.40 | 20.55Average 20.5 Average | 42.11%Excellent 42.11% Excellent | 18.49%Good 18.49% Good | 0.00Excellent 0.0 Excellent | 15.08%Excellent 15.08% Excellent | -41.25%Poor -41.25% Poor | 0.00% |
Syngene International LimitedSyngene Interna... SYNGENE • 539268 | 35.4/100 | ₹384.20₹384 | ₹15510.15₹15510.15 | 69.85Average 69.9 Average | 0.00%Poor 0.00% Poor | 8.43%Poor 8.43% Poor | 0.00Excellent 0.0 Excellent | -0.98%Poor -0.98% Poor | 11.35%Good 11.35% Good | 0.30% |
Indegene LimitedIndegene Limite... INDGN • 544172 | 57/100 | ₹582.80₹583 | ₹14016.34₹14016.34 | 34.88Average 34.9 Average | 13.94%Average 13.94% Average | 17.29%Good 17.29% Good | 0.00Excellent 0.0 Excellent | 23.02%Excellent 23.02% Excellent | 29.44%Excellent 29.44% Excellent | 0.39% |
Suven Life Sciences LimitedSuven Life Scie... SUVEN • 530239 | 11.4/100 | ₹358.55₹359 | ₹9465.47₹9465.47 | — — | -78.80%Poor -78.80% Poor | -78.35%Poor -78.35% Poor | 0.00Excellent 0.0 Excellent | — — | -12.00%Poor -12.00% Poor | 0.00% |
Vimta Labs LimitedVimta Labs Limi... VIMTALABS • 524394 | 63.6/100 | ₹623.00₹623 | ₹2782.94₹2782.94 | 34.88Average 34.9 Average | 18.55%Good 18.55% Good | 23.39%Excellent 23.39% Excellent | 0.01Excellent 0.0 Excellent | 29.35%Excellent 29.35% Excellent | 14.09%Good 14.09% Good | 0.35% |
NOVELIX PHARMACEUTICALS LIMITENOVELIX PHARMAC... NOVELIX • 536565 | 56.9/100 | ₹79.00₹79 | ₹166.57₹166.57 | 45.85Average 45.8 Average | 8.00%Poor 8.00% Poor | 9.96%Poor 9.96% Poor | 0.09Excellent 0.1 Excellent | 22.72%Excellent 22.72% Excellent | 151.69%Excellent 151.69% Excellent | 0.00% |
Bilcare LimitedBilcare Limited... BI • 526853 | 28.9/100 | ₹93.01₹93 | ₹147.94₹147.94 | 26.80Average 26.8 Average | 1.66%Poor 1.66% Poor | 5.56%Poor 5.56% Poor | 3.15Poor 3.1 Poor | 16.32%Excellent 16.32% Excellent | 3.33%Average 3.33% Average | 0.00% |
Adeshwar Meditex LtdAdeshwar Medite... ADESHWAR • 543309 | 24.6/100 | ₹16.30₹16 | ₹23.52₹23.52 | 19.47Average 19.5 Average | 3.38%Poor 3.38% Poor | 6.02%Poor 6.02% Poor | 0.16Excellent 0.2 Excellent | -6.68%Poor -6.68% Poor | -3.19%Poor -3.19% Poor | 0.00% |
Vanta Bioscience LtdVanta Bioscienc... VANTABIO • 540729 | 23.9/100 | ₹19.60₹20 | ₹13.94₹13.94 | 163.55Average 163.6 Average | 0.76%Poor 0.76% Poor | 1.39%Poor 1.39% Poor | 1.80Average 1.8 Average | -24.21%Poor -24.21% Poor | -28.62%Poor -28.62% Poor | 0.00% |
Top Healthcare Research, Analytics & Technology Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Syngene International Limited share price15510.15 Cr
- Indegene Limited share price14016.34 Cr
- Suven Life Sciences Limited share price9465.47 Cr
- Vimta Labs Limited share price2782.94 Cr
- NOVELIX PHARMACEUTICALS LIMITE share price166.57 Cr
TAKE Limited PE Ratio History
Historical price-to-earnings ratio for TAKE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.56 | ₹39.94 | 15.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
TAKE Limited Dividend History
Annual cash dividends paid by TAKE — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.04 Cr |
| FY 2024 | ₹0.07 Cr |
| FY 2023 | ₹0.07 Cr |
| FY 2022 | ₹0.01 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
TAKE Limited Quarterly Performance
Latest quarterly metrics for TAKE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-216.76%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-41.25%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.08%
Compounded annual net profit growth over 5 years
TAKE Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TAKE — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
TAKE Limited Financial Statements
Annual income statement, balance sheet and cash flow for TAKE Limited (TAKE) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for TAKE Limited
About TAKE (TAKE Limited)
Take Solutions Ltd is a global technology company at the forefront of healthcare research, analytics, and technology. They are a dynamic force driving innovation across the healthc...are ecosystem. Specializing in intricate data analysis and technological solutions, TAKE empowers healthcare organizations to unlock valuable insights, optimize processes, and improve patient outcomes. Their commitment extends beyond simply offering services; it's about partnering with clients to navigate the ever-evolving landscape of healthcare, leveraging advanced analytics and cutting-edge technology to pave the way for meaningful advancements. Take Solutions works to transform data into actionable knowledge. TAKE provides an array of specialized services designed to address the unique challenges within the life sciences and healthcare sectors. Their expertise encompasses a broad spectrum, including clinical research support, advanced analytics for drug development, and solutions for regulatory compliance. They delve deep into healthcare data to identify trends, predict outcomes, and enhance the efficiency of research and development processes. This in-depth approach enables clients to make informed decisions, accelerate innovation, and ensure the highest standards of quality and safety in the development and delivery of healthcare products and services. TAKE's holistic approach leverages digital transformation and mobile solutions, improving the patient experience while generating payer insights. They are dedicated to pushing the boundaries of what's possible in healthcare, working with clients to create a healthier future for all. Their solutions are meticulously crafted to meet the specific needs of each client, ensuring that they receive customized support and achieve optimal results. With a focus on innovation, collaboration, and a commitment to excellence, TAKE Solutions Ltd is a driving force in the transformation of the healthcare industry.
Company Details
Key Leadership
TAKE Share Price: Frequently Asked Questions
What is the current share price of TAKE Limited?
TAKE Limited (TAKE) trades at ₹17.67 on NSE and BSE. Market cap ₹261.40 (Cr). Educational data only.
What is the P/E ratio of TAKE Limited?
TAKE Limited has a P/E of 20.55x vs industry average 39.78x.
What is the Bull Run score for TAKE Limited?
TAKE Limited has a Bull Run score of 31.2/100 based on 25+ financial parameters.
Does TAKE Limited pay dividends?
TAKE Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of TAKE Limited?
TAKE Limited has ROE of 42.11%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of TAKE Limited?
TAKE Limited has debt-to-equity of 0.00.
Is TAKE Limited a good investment?
Bull Run gives TAKE Limited a score of 31.2/100. This is not investment advice — consult a SEBI-registered advisor.